←
David H Aggen, MD PhD2,180 posts
David H Aggen, MD PhD avatar✓

David H Aggen, MD PhD ✓

@Dr_Aggen

Assistant Attending, MSKCC, Genitourinary Oncology Service Tweets are my own opinions and do not represent the views or opinions of Memorial Sloan Kettering

◷ Joined May 2016▧ 268 Photos and videos
David H Aggen, MD PhD avatar
David H Aggen, MD PhD@Dr_Aggen·May 31

🧬 What happens to Nectin-4 expression after EV+pembro? New paired biopsy data from @MichalSternsch @MSKCancerCenter at #ASCO2026: some tumors retain membranous Nectin-4 post-EVP — complete target loss is seen in some cases of early progression - and in 6/6 post EV/P tumors at cystectomy Nectin-4 expression decreased in residual tumors. | Abstract 552910, Poster A56 #BladderCancer

Post attachment
Juan C Osorio MD avatar
⟳ David H Aggen, MD PhD retweeted
Juan C Osorio MD@juanosoriomd·14h

Excited to share our study, published today in @CCR_AACR Can we harness CD40 agonism to treat bladder cancer? And how spatial immune organization within tumors correlate with response? We report findings from a phase I trial of our Fc-engineered CD40 agonist. 🧵🪡 link 👇

David H Aggen, MD PhD avatar
David H Aggen, MD PhD@Dr_Aggen·Nov 16

Trials are critical for defining what comes after EV + pembrolizumab (EV/P) in advanced bladder cancer? 🧵 1/9 At @MSKCancerCenter with @MSK_DeptOfMed @UrologyMSK we're exploring all these approaches through several clinical trials to overcome EV resistance New Patients Contact for appointments: 866-432-3416 mskcc.org/experience/become-… - NEW cancer targets (TROP2, EGFR/HER3) - NEW ADC payloads (Topo-I) - T-cell engagers - Radioligand therapies @MSK_DeptOfMed #blcsm

Post attachment